Company intelligence / Profile preview

TD Peptide Bio

Russia

Ownership: Private
Development stage: Other

Overview

TD Peptide Bio produces and markets peptide-based dietary supplements with anti-aging and wellness applications, relying on over 30 years of clinical observations and research. Their products are manufactured to international standards and promoted as unique in the global market; no peer-reviewed clinical trial results are available for drug claims.

Therapeutic areas: CardiovascularOncologyOther
Modalities: PeptidesDietary supplement
Industry: Food & Nutrition

Partnerships

St. Petersburg Institute of Bioregulation and GerontologyEuropean pharmaceutical companies

Beyond the preview

Go deeper on TD Peptide Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TD Peptide Bio.

Explore the full profile